SUBJECT INDEX (-)-Epigallocatechin-3-gallate 2919-PO Add-on to basal insulin 1102-P Aggressiveness factor 2526-PO 1,5-Anhydroglucitol 928-P Add-on to metformin 1092-P Aging 1284-P, 1396-P, 1399-P, 1797-P, 1966-P, 11 β-HSD 1993-P Add-on to metformin + SU 1082-P 1972-P, 1981-P, 2007-P, 2209-P, 2308-PO, 11beta-HSD, glucocorticosteroids, type 2 diabetes Add-on to pioglitazone 1120-P 2481-PO, 2693-PO, 2697-PO 1128-P Adenine nucleotide translocase 28-OR, 29-OR Aging society 2657-PO 11β-HSD1 1875-P Adenosine A1 receptor 1854-P Agreement 2508-PO SUBJECT INDEX 12(S)-HETE 2057-P Adenovirus, shrna, over expression 340-OR Agrp neurons 1917-P 12/15-Lipoxygenase 2057-P Adherence 652-P, 789-P, 802-P, 814-P, 821-P, 857-P, AICAR 1815-P 12-Lipoxygenase 338-OR 889-P, 894-P, 1227-P, 1259-P, 1423-P, 2504-PO Akita 1643-P 14-3-3 142-OR Adhesive capsulitis 2887-PO Akt 25-OR 18FDG PET 2026-P Adipocyte 100-OR, 1644-P, 1748-P, 1748-P, 1749-P, Akt mediated signaling pathway 2321-PO 18F-TTCO-cys40-exendin-4 2163-P 1751-P, 1752-P, 1755-P, 1756-P, 1758-P, 1761-P, Akt, glucose uptake 1802-P 1-h plasma glucose 1457-P, 2808-PO 1763-P, 1765-P, 1769-P, 1769-P, 2056-P, 2943-PO Akt/GSK3 signaling pathway 488-P 25(OH)D 679-P Adipocyte differentiation 144-OR, 1745-P, 1745-P, Akt2 1818-P 25-hydroxivitamin D 2035-P 2013-P Alanine 1916-P 26S Proteasomes 498-P Adipocyte fatty acid-binding protein 2003-P Alanine aminotransferase 1460-P, 2860-PO 2-Aminobicyclo-(2,2,1)-heptane-2-carboxylic acid Adipocyte precursor cells 2081-P Alaska native people 183-OR 2079-P Adipocytes 94-OR, 95-OR, 1750-P Albiglutide 68-OR, 1010-P, 1044-P, 2590-PO 2-hour plasma glucose 1399-P Adipocytokines 1753-P, 2338-PO Albumin to creatinine ratio 2722-PO 3D microscopy 361-OR Adipogenesis 142-OR, 302-OR, 1752-P, 1763-P, Albuminuria 103-OR, 108-OR, 417-P, 419-P, 472-P, 3-hydroxybutyrate 2521-PO 2069-P, 2074-P, 2086-P, 2113-P 520-P, 555-P, 557-P, 559-P, 572-P, 719-P, 719-P, 3T3-L1 2921-PO Adipokine 1296-P, 1331-P, 1386-P, 2109-P, 2109-P, 1293-P, 1293-P, 1307-P, 1523-P, 2377-PO, 4-1BB 1719-P 2677-PO, 2686-PO 2387-PO, 2629-PO, 2725-PO 6q24 129-OR Adiponectin 202-OR, 250-OR, 446-P, 474-P, 624-P, Alcohol consumption 2267-P 7-point profile 906-P 650-P, 761-P, 1356-P, 1463-P, 1467-P, 1506-P, Aldose reductase inhibitor 577-P 9p21 locus 1505-P 1610-P, 1884-P, 2092-P, 2131-P, 2209-P, 2591-PO Aldosterone 566-P, 762-P, 2000-P A meta-analysis 1521-P Adiponectin multimer 741-P Aleglitazar 1142-P A1C 861-P, 877-P, 900-P, 1152-P, 1474-P, 1487-P, Adiponectin receptor 1807-P Aliskiren 566-P, 1191-P 1497-P, 1516-P, 1640-P, 2542-PO Adipor 64-OR, 202-OR All-cause mortality 278-OR A1c registry 2-OR Adipose 1637-P, 1743-P, 2102-P, 2102-P Alloreactive T cells 287-OR AATK 195-OR Adipose tissue 63-OR, 168-OR, 1744-P, 1803-P, All-trans retinoic acid 2907-PO Abdominal obesity 1909-P 1812-P, 1951-P, 2105-P, 2105-P, 2110-P, 2159-P Alogliptin 1143-P, 2621-PO, 2647-PO Abnormal glucose tolerance 1466-P Adipose tissue browning 1917-P Alpha cell 1053-P, 2851-PO Abnormal glycorgulation 1492-P Adipose tissue inflammation 99-OR Alpha glucosidase inhibitors 2628-PO Aboriginal 1535-P Adipose tissue insulin resistance 2104-P Alpha lipoic acid 592-P, 2923-PO Acabose 2626-PO Adipose tissue restriction 1856-P Alpha-1-microglobulin 2375-PO Academics 1349-P Adipose tissue secretion 2095-P Alpha-glucosidase inhibitor 2150-P Acanthosis nigricans 2677-PO Adiposity 2042-P Alphatc1-9 2286-P Acarbose 2150-P Administrative claims 1426-P Alternative splicing 1759-P ACC2 1776-P Administrative database 1268-P, 2306-PO Alzheimer’s disease 595-P, 600-P, 1181-P Access to food 755-P Admission glucose 2766-PO Ambulatory blood pressure 550-P ACCORD 207-OR, 709-P, 1065-P Admission hyperglycemia 478-P American indian 1666-P, 2465-PO Accuracy 391-P, 873-P, 874-P, 899-P, 904-P Admissions avoidance 1248-P Amino acid 1125-P, 1451-P ACE gene insertion/deletion polymorphism Adolescents 82-OR, 734-P, 789-P, 790-P, 791-P, Ammonia 1916-P 2331-PO 824-P, 827-P, 835-P, 847-P, 1291-P, 1293-P, AMPK 34-OR, 36-OR, 253-OR, 254-OR, 1050-P, ACE2 719-P, 2291-P 1307-P, 1314-P, 1324-P, 1327-P, 1337-P, 1342-P, 1814-P, 1815-P, 1876-P, 1893-P, 1895-P, 1916-P, Acetyl coa inhibition 636-P 1349-P, 1352-P, 2407-PO, 2504-PO, 2673-PO, 1940-P, 1941-P, 1966-P, 2050-P Acetylation 28-OR 2874-PO Amputation 118-OR, 120-OR, 672-P, 672-P, 2437-PO, Acetylcholine receptor 2283-P Adrenergic signaling 1810-P 2439-PO Acetyl-coa carboxylase (ACC) β 519-P Adults 842-P, 808-P Amygdala 2053-P Actin 1756-P Advanced diabetic nephropathy 548-P Amylin 2167-P Actin cytoskeleton 2075-P Advanced glycation end products 57-OR, 104-OR, Amyloid 300-OR Action potential 599-P 205-OR, 426-P, 1208-P, 1333-P, 1348-P, 1920-P, Anabolic metabolism 616-P Active comparator 238-OR 1937-P, 2409-PO, 2738-PO Ancestry 86-OR, 1540-P Acute complications 2788-PO Advanced practice nurse 318-OR Androgen receptor 2226-P Acute coronary syndrome 349-OR, 459-P, 478-P, Advanced type 2 diabetes 70-OR Angiogenesis 576-P, 610-P, 668-P, 668-P, 1726-P, 1253-P, 1415-P Adverse event 275-OR 2077-P, 2469-PO Acute inflammatory response 1627-P Adverse outcomes 1270-P Angiogrography 2436-PO Acute insulin response 1652-P Aerobic exercise 216-OR, 1890-P Angiotensin 1-7 1964-P Acute phase reactants 421-P Africa 1485-P, 2786-PO Angiotensin II 1854-P, 2910-PO Acute stroke 2711-PO African american 217-OR, 322-OR, 2099-P Angiotensin receptor blocker 1804-P ADAM17 and ACE2 shedding 2367-PO African american women 182-OR, 706-P Animal model 2843-PO, 2922-PO Adaptive control 2582-PO AG average glucose 2542-PO Ankle-brachial index 119-OR, 588-P Adaptive optics 154-OR Age 92-OR, 560-P, 625-P, 962-P, 1208-P, 1210-P, ANRIL 449-P ADCY5 1635-P 1397-P, 1519-P, 1597-P, 2415-PO Ansiscope 2402-PO Addition study 2721-PO AGE reader 1519-P Anti CD3 antibody 1705-P Additivity 909-P Age related macular degeneration 2409-PO Antibiotic eradication 192-OR OR-Oral P-Poster PO-Published Only A755 Antibody 1687-P Audit impact 2671-PO 2213-P, 2235-P, 2263-P, 2263-P, 2266-P, Anticancer agent 2767-PO Autoantibodies 128-OR, 1611-P, 1839-P 2271-P,2278-P, 2282-P, 2292-P, 2294-P, 2294B-P, Antidiabetic medication 209-OR Autoantigen 1700-P 2520-PO, 2823-PO, 2851-PO, 2968-PO Antihyperglycemic agents 1030-P Autoimmune 246-OR, 1626-P Beta cell apoptosis 199-OR, 336-OR, 2162-P, 2171-P Anti-inflammation 377-OR, 1678-P, 1703-P, 2052-P Autoimmune regulator (AIRE) 1692-P Beta cell biology 2244-P Anti-obesity 2052-P Autoimmunity 19-OR, 282-OR, 1207-P, 1475-P, Beta cell compensation 2219-P Anti-oxidant 1078-P, 1740-P, 2170-P, 2977-PO 1714-P, 2166-P, 2431-PO Beta cell dysfunction 335-OR, 1578-P, 1832-P Antioxidant enzyme defense 607-P Autoislets 362-OR Beta cell function 80-OR, 163-OR, 199-OR, Antipsychotic 150-OR, 317-OR, 2138-P Automated insulin delivery 228-OR 427-P,954-P, 981-P, 1028-P, 1117-P, 1138-P, SUBJECT INDEX Anxa1 2967-PO Automatic messages 867-P 1292-P, 1292-P, 1402-P, 1402-P, 1462-P, 1492-P, Anxiety 775-P, 787-P, 844-P Automatic suspension 974-P 1547-P, 1688-P, 1825-P, 1828-P, 1829-P, 1835-P, Aortic stiffness 1413-P, 2328-PO Autonomic neuropathy 53-OR, 131-OR, 593-P, 1838-P, 1842-P, 2153-P, 2185-P, 2228-P, 2284-P, Apnea hypopnea index 1302-P 2395-PO 2697-PO, 2717-PO,2847-PO Apo a-I 2249-P Autophagy 60-OR, 512-P, 539-P, 1784-P, 1801-P, Beta cell mass 44-OR, 46-OR, 195-OR, 341-OR, Apoe polymorphism 637-P 1864-P, 1915-P, 2178-P, 2183-P, 2336-PO, 2803-PO 2258-P, 2915-PO Apolipoprotein A-I 303-OR Autoreactive T cells 288-OR Beta cell preservation 2572-PO Apolipoprotein B 355-OR, 659-P, 2422-PO Avanafil 585-P Beta cell proliferation 46-OR, 1686-P, 2193-P, Apoptosis 203-OR, 288-OR, 492-P, 502-P, 590-P, Avandamet 2639-PO 2200-P 1795-P, 2093-P, 2165-P, 2170-P, 2172-P, 2176-P, Average plasma glucose 2532-PO Beta cell protection 110-OR, 338-OR 2187-P, 2292-P Azelnidipine 1204-P Beta cell regeneration 1729-P, 2040-P, 2634-PO, Appetite regulation 2106-P B lymphocyte 291-OR 2642-PO, 2966-PO APPL1 2182-P B12 1062-P, 1068-P Beta cell rest 2236-P Appointment adherence 1240-P B7.